2nd May 2006 16:30
AstraZeneca PLC02 May 2006 Dealing by DirectorsCompanies Act 1985 Sections 324/329 We hereby inform you that the interest of David R Brennan, a Director of theCompany, in the American Depositary Shares (ADSs) of AstraZeneca PLC has changedas detailed below. One ADS equals one Ordinary Share. As previously notified on 28 March 2006, Mr Brennan became unconditionallyentitled to 31,780 ADSs on the partial vesting of an award under the terms ofthe AstraZeneca US Executive Performance Share Plan. At that time, Mr Brennanelected to defer the value of those ADSs, less certain mandatory tax deductions,into the AstraZeneca US Executive Deferred Compensation Plan, a unitised stockfund in which Mr Brennan, in common with other participating US executives, isdeemed to have a notional interest in ADSs calculated by reference to the fundvalue and the closing price of AstraZeneca ADSs. This deferral occurredautomatically on 28 April 2006, following which Mr Brennan has a notionalinterest in 28,831 ADSs in the AstraZeneca US Executive Deferral Plan as at 28April 2006 based on that day's closing price of US$55.13. In total, Mr Brennan now has an interest in 167,453 AstraZeneca ADSs and 79,461Ordinary Shares, including the notional interest in ADSs in the AstraZeneca USExecutive Deferred Compensation Plan referred to above. G H R MuskerCompany Secretary2 May 2006 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca